SOURCES
References you can consult.
Official information and identifiable publications used in the guides. Read original dates at their publishers.
- HAS — care pathway for overweight and obesity (French)
- Santé publique France — food and activity guidance (French)
- Assurance Maladie — everyday changes (French)
- NIH ODS — weight-loss supplements
- Anses — Garcinia cambogia adverse effects, 2025 (French)
- Anses — sports supplements, 2016 report (French)
- Anses — weight-loss diet risks, 2010 report (French)
- Assurance Maladie — food and medicine interactions (French)
- EMA — Ozempic authorisation and medicine information
- EMA — Wegovy indications and medicine information
- ANSM — appropriate use of Ozempic (French)
- Wilding et al. — STEP 1 randomised trial, NEJM, 2021
- EMA — Mounjaro indications and medicine information
- Aronne et al. — SURMOUNT-5 randomised comparison, NEJM, 2025
- EFSA — glucomannan opinion, 2010
- Anses — Withania somnifera assessment, 2024 (French)
- Anses — turmeric and liver effects, 2022 (French)
- EMA — sibutramine suspension procedure, 2010
- EMA — current Wegovy product information
- EMA — NAION as a very rare semaglutide adverse effect, 2025
Read the limitations
Citation does not mean a source endorses this website. Regulatory documents, studies and historical reports answer different questions. Formulations, presentations and French conditions can change: check relevant information when making a decision.